NEW YORK, July 20, 2015 /PRNewswire/ --
Equity Research Institute has initiated coverage on the following equities: Achillion Pharmaceuticals Inc. (NASDAQ : ACHN ), CTI BioPharma Corporation (NASDAQ : CTIC ), Enzon Pharmaceuticals Inc. (NASDAQ : ENZN ), Discovery Laboratories Inc. (NASDAQ : DSCO ), and Pacific Biosciences of California Inc. (NASDAQ : PACB ). Free research report on Achillion Pharma can be accessed at https://www.EquityResearchInstitute.com/reports?keyword=ACHN On Friday, July 17, 2015, the NASDAQ Composite ended at 5,210.14, up 0.91%, the Dow Jones Industrial Average declined 0.19%, to finish the day at 18,086.45, and the S&P 500 closed at 2,126.64, up 0.11%. The losses were broad based as six out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.
On Friday, shares in Achillion Pharmaceuticals Inc. ended the session 0.42% lower at $9.43. The stock reported a trading volume of 1.86 million shares, below its three months average volume of 3.32 million shares. Although, Achillion Pharmaceuticals Inc.'s shares have gained 8.89% in the last one month, it has lost 8.09% in the previous three months and 23.02% on YTD basis. The company is trading 3.47% above its 50-day moving average. Moreover, shares of Achillion Pharmaceuticals Inc. have a Relative Strength Index (RSI) of 56.08. Sign up and read the free notes on ACHN at:
CTI BioPharma Corp.'s stock closed the day flat at $1.95. The stock recorded a trading volume of 0.85 million shares, much below its three months average volume of 3.24 million shares. Over the last one month and since the start of this year, CTI BioPharma Corp.'s shares have lost 7.58% and 17.37%, respectively. However, the stock has advanced 7.14% in the previous three months. The company's shares are trading 0.29% below their 50-day moving average. Additionally, CTI BioPharma Corp. has an RSI of 49.22. The complimentary notes on CTIC can be downloaded in PDF format at:
On Friday, shares in Enzon Pharmaceuticals Inc. recorded a trading volume of 0.88 million shares, lower than their three months average volume of 3.27 million shares. The stock ended the day 4.88% lower at $1.56. Shares of the company traded at a PE ratio of 2.52. Enzon Pharmaceuticals Inc.'s stock has surged 20.00% in the last one month, 20.93% in the previous three months and 57.72% on YTD basis. The company is trading above its 50-day and 200-day moving averages by 18.24% and 40.86%, respectively. Furthermore, shares of Enzon Pharmaceuticals Inc. have an RSI of 59.66. Register for free on Equity Research Institute and access the latest research on ENZN at:
Discovery Laboratories Inc.'s stock plummeted 15.54%, to close Friday's session at $0.52. The stock recorded a trading volume of 1.43 million shares, above its three months average volume of 0.59 million shares. Over the last one month and the previous three months, Discovery Laboratories Inc.'s shares have declined 34.78% and 54.00%, respectively. Additionally, the stock has lost 55.59% since the start of this year. The company is trading 35.68% and 60.11% below its 50-day and 200-day moving averages, respectively. Furthermore, Discovery Laboratories Inc.'s stock has an RSI of 25.83. The complete research on DSCO is available for free at:
Pacific Biosciences of California Inc.'s stock finished Friday's session 0.37% higher at $5.38. A total of 0.29 million shares were traded, which was below its three months average volume of 0.54 million shares. Over the previous three months and since the beginning of 2015, Pacific Biosciences of California Inc.'s shares have declined 12.52% and 31.38%, respectively. However, the stock has gained 1.13% in the last one month. The company's shares are trading below their 50-day and 200-day moving averages by 4.44% and 14.46%, respectively. Pacific Biosciences of California Inc.'s stock has an RSI of 48.38. Free in-depth research on PACB is available at:
About Equity Research Institute:
Equity Research Institute ("ERI") produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. ERI has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
ERI has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the "CFA®"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer and the CFA® have not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author, the Reviewer, or the CFA® (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein.
ERI, the Author, the Reviewer and the CFA® (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither ERI nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.equityresearchinstitute.com.
ERI is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia. Do not send email to robottrap (at) equityresearchinstitute.com.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.